^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    KROS-201

    i
    Other names: KROS-201, activated T cells
    Associations

    News

    Trials
    Company:
    Kairos Pharma
    Drug class:
    T-cell stimulant
    Related drugs:
    Associations

    News

    Trials
    6ms
    Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With Recurrent Glioblastoma (clinicaltrials.gov)
    P1, N=10, Not yet recruiting, Jeremy Rudnick, M.D | Trial completion date: Jun 2025 --> Dec 2026 | Trial primary completion date: Jun 2023 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    KROS-201
    over2years
    Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With Recurrent Glioblastoma (clinicaltrials.gov)
    P1, N=10, Not yet recruiting, Jeremy Rudnick, M.D
    New P1 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • IL13RA2 (Interleukin 13 Receptor Subunit Alpha 2)
    |
    CD133 expression • HLA-A2 positive
    |
    KROS-201